IRWD Ironwood Pharmaceuticals Inc - Class A

Price (delayed)

$3.46

Market cap

$571.73M

P/E Ratio

4.33

Dividend/share

N/A

EPS

$0.8

Enterprise value

$889.47M

?
Relative Growth: Rel. Growth: 76
Relative Strength: Rel. Strength: 49
Relative Valuation: Rel. Valuation: 98
Relative Profitability: Rel. Profitability: 94

Ironwood Pharmaceuticals is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog ...

Highlights
IRWD's P/E is 57% below its last 4 quarters average of 10.0
The company's equity rose by 47% YoY and by 25% QoQ

Key stats

What are the main financial stats of IRWD

IRWD stock price

How has the Ironwood Pharmaceuticals stock price performed over time
Intraday
-1.14%
1 week
-1.14%
1 month
-4.95%
1 year
80.21%
YTD
2.67%
QTD
-12.85%

Financial performance

How have Ironwood Pharmaceuticals's revenue and profit performed over time
Revenue
$389.32M
Gross profit
$389.32M
Operating income
$234.17M
Net income
$129.87M
Gross margin
100%
Net margin
33.4%
IRWD's operating margin has surged by 153% year-on-year and by 8% since the previous quarter
The net income has grown by 27% from the previous quarter
IRWD's revenue is up by 26% YoY and by 8% QoQ
Ironwood Pharmaceuticals's gross profit has increased by 26% YoY and by 8% QoQ

Price vs fundamentals

How does IRWD's price correlate with its fundamentals

Growth

What is Ironwood Pharmaceuticals's growth rate over time

Valuation

What is Ironwood Pharmaceuticals stock price valuation
P/E
4.33
P/B
N/A
P/S
1.46
EV/EBIT
3.71
EV/EBITDA
3.65
EV/Sales
2.28
IRWD's P/E is 57% below its last 4 quarters average of 10.0
The EPS has increased by 25% since the previous quarter
The company's equity rose by 47% YoY and by 25% QoQ
IRWD's P/S is 48% below its 5-year quarterly average of 2.8 and 2.7% below its last 4 quarters average of 1.5
IRWD's revenue is up by 26% YoY and by 8% QoQ

Efficiency

How efficient is Ironwood Pharmaceuticals business performance
The return on sales has surged by 145% year-on-year and by 9% since the previous quarter
Ironwood Pharmaceuticals's return on assets has increased by 32% QoQ
Ironwood Pharmaceuticals's ROIC has increased by 19% from the previous quarter

Dividends

What is IRWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IRWD.

Financial health

How did Ironwood Pharmaceuticals financials performed over time
The total assets is 36% less than the total liabilities
The total assets has contracted by 34% from the previous quarter and by 17% YoY
IRWD's total liabilities is down by 31% since the previous quarter and by 31% year-on-year
The company's equity rose by 47% YoY and by 25% QoQ
IRWD's debt is down by 34% year-on-year and by 34% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.